LNS-8801 as a therapeutic agent for aggressive lymphomas: ROS-induced cytotoxicity and synergy with existing therapies.

IF 7.4 1区医学 Q1 HEMATOLOGY

Blood advances Pub Date : 2025-04-18 DOI:10.1182/bloodadvances.2025016199

Yang Li, Corinna Kosnopfel, Daniela Schwammbach, Ling Jin, Michael Grau, Georg Lenz, Stephan Hailfinger

引用次数: 0

查看原文本刊更多论文

LNS-8801作为侵袭性淋巴瘤的治疗剂：ros诱导的细胞毒性及其与现有疗法的协同作用

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood advances Medicine-Hematology

CiteScore

12.70

自引率

2.70%

发文量

840

期刊介绍： Blood Advances, a semimonthly medical journal published by the American Society of Hematology, marks the first addition to the Blood family in 70 years. This peer-reviewed, online-only, open-access journal was launched under the leadership of founding editor-in-chief Robert Negrin, MD, from Stanford University Medical Center in Stanford, CA, with its inaugural issue released on November 29, 2016. Blood Advances serves as an international platform for original articles detailing basic laboratory, translational, and clinical investigations in hematology. The journal comprehensively covers all aspects of hematology, including disorders of leukocytes (both benign and malignant), erythrocytes, platelets, hemostatic mechanisms, vascular biology, immunology, and hematologic oncology. Each article undergoes a rigorous peer-review process, with selection based on the originality of the findings, the high quality of the work presented, and the clarity of the presentation.